Post by troyhather on Oct 4, 2017 5:58:46 GMT
Research in representative patient groups including full assessment of perceived benefits and harms of the process of screening, impact of diagnosis using the existing evidence to guide the specific questions.
To scrutinise whether stratification on the basis of easily available data could identify those most likely to benefit, and those where harm/benefit may reverse. To conduct careful trials if the question does not have sufficient existing evidence to answer.
Learning from current clinical and funded future research about the characterisation of early dementia and pre-dementia patients is likely to provide benefit, and how this may translate into population settings including recognition of multiple causes of underlying syndrome and proximity to death (that is, value of diagnosis in last years of life in a frail older population). From the above continue search for biomarkers that reflect the person and their individual prognosis better.
Develop screening diagnostic aids with sufficient robustness: appropriate for setting/age group/comorbidity.
For any technology or diagnostic boundary change with potential to ‘creep’ into usual clinical practice conduct economic studies which are appropriate to specific clinical settings and their particular populations.
To scrutinise whether stratification on the basis of easily available data could identify those most likely to benefit, and those where harm/benefit may reverse. To conduct careful trials if the question does not have sufficient existing evidence to answer.
Learning from current clinical and funded future research about the characterisation of early dementia and pre-dementia patients is likely to provide benefit, and how this may translate into population settings including recognition of multiple causes of underlying syndrome and proximity to death (that is, value of diagnosis in last years of life in a frail older population). From the above continue search for biomarkers that reflect the person and their individual prognosis better.
Develop screening diagnostic aids with sufficient robustness: appropriate for setting/age group/comorbidity.
For any technology or diagnostic boundary change with potential to ‘creep’ into usual clinical practice conduct economic studies which are appropriate to specific clinical settings and their particular populations.